Drug firm Lupin today said its wholly-owned American subsidiary has received the final approval from the US health regulator for its generic Hyzaar and Cozaar tablets used for treating high blood pressure.
"The approval has been given to Lupin Pharmaceuticals Inc for Merck's branded Hyzaar(hydrochlorothiazide; losartan potassium) and Cozaar(losartan potassium) tablets by the United States Food and Drug Administration," Lupin Limited said in a filing to the Bombay Stock Exchange.
Hyzaar and Cozaar had a combined annual sales of nearly $1.6 billion, based on IMS sales data for the financial year ended June 2010, it added.
Lupin produces a wide range of quality, affordable generic and branded formulations and active pharmaceutical ingredients (APIs) for the developed and developing markets of the world.
Shares of Lupin closed at Rs 405.60 on the BSE, up 2.23 per cent from its previous close.
